Literature DB >> 10935490

ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

D Smedley1, A Demiroglu, M Abdul-Rauf, C Heath, C Cooper, J Shipley, N C Cross.   

Abstract

The ZNF198- FGFR1 fusion gene arises as a result of the t(8;13)(p11;q12) in the 8p11 myeloproliferative syndrome. To determine the transforming properties of this chimeric protein we transfected ZNF198-FGFR1 into the interleukin (IL)-3 dependent cell line Ba/F3. Growth factor independent subclones were obtained in which ZNF198-FGFR1, STAT1, and STAT5 were constitutively tyrosine phosphorylated, as determined by immunoprecipitation and Western blot analysis. To test the hypothesis that constitutive activation of ZNF198-FGFR1 tyrosine kinase activity is a result of self-association of the fusion protein, we in vitro transcribed and translated ZNF198-FGFR1 and a derivative construct, ZNF198- FGFR1deltaC-myc, in which the C-terminal FGFR1 epitope was replaced by a c-myc tag. As expected, an anti-FGFR1 antibody immunoprecipitated ZNF198-FGFR1 but not ZNF198-FGFRdeltaC-myc. However when both products were translated together, both were coimmunoprecipitated by anti-FGFR1 antisera. Similar results were obtained by using an anti-myc antibody and demonstrated a physical interaction between the two proteins. Analysis of COS-7 cells transfected with ZNF198-FGFR1 demonstrated that the fusion gene, in contrast to normal FGFR1, is located in the cytoplasm. We conclude that ZNF198-FGFR1 is a cytoplasmic protein that self-associates and has constitutive transformation activity. These data suggest that ZNF198-FGFR1 plays a primary role in the pathogenesis of the t(8;13) myeloproliferative syndrome and is the first report to implicate STAT proteins in FGFR1-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10935490      PMCID: PMC1508104          DOI: 10.1038/sj.neo.7900035

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  38 in total

1.  Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction.

Authors:  M Mohammadi; I Dikic; A Sorokin; W H Burgess; M Jaye; J Schlessinger
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

2.  The novel activation of ABL by fusion to an ets-related gene, TEL.

Authors:  P Papadopoulos; S A Ridge; C A Boucher; C Stocking; L M Wiedemann
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

3.  p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl.

Authors:  R Salgia; M Sattler; E Pisick; J L Li; J D Griffin
Journal:  Exp Hematol       Date:  1996-02       Impact factor: 3.084

4.  Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.

Authors:  M Wetzler; M Talpaz; R A Van Etten; C Hirsh-Ginsberg; M Beran; R Kurzrock
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

5.  Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.

Authors:  T R Golub; G F Barker; M Lovett; D G Gilliland
Journal:  Cell       Date:  1994-04-22       Impact factor: 41.582

6.  Stem cell factor and basic fibroblast growth factor are synergistic in augmenting committed myeloid progenitor cell growth.

Authors:  J L Gabrilove; K White; Z Rahman; E L Wilson
Journal:  Blood       Date:  1994-02-15       Impact factor: 22.113

7.  Basic fibroblast growth factor mediates its effects on committed myeloid progenitors by direct action and has no effect on hematopoietic stem cells.

Authors:  A C Berardi; A Wang; J Abraham; D T Scadden
Journal:  Blood       Date:  1995-09-15       Impact factor: 22.113

8.  Reduced activation of RAF-1 and MAP kinase by a fibroblast growth factor receptor mutant deficient in stimulation of phosphatidylinositol hydrolysis.

Authors:  J Huang; M Mohammadi; G A Rodrigues; J Schlessinger
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

Review 9.  A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review.

Authors:  D Macdonald; R C Aguiar; P J Mason; J M Goldman; N C Cross
Journal:  Leukemia       Date:  1995-10       Impact factor: 11.528

10.  An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.

Authors:  J R McWhirter; J Y Wang
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

View more
  12 in total

1.  STAT5 acts as a repressor to regulate early embryonic erythropoiesis.

Authors:  Matthew Schmerer; Ingrid Torregroza; Aude Pascal; Muriel Umbhauer; Todd Evans
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

2.  Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

Authors:  Xiaohui Lu; Ross Levine; Wei Tong; Gerlinde Wernig; Yana Pikman; Sara Zarnegar; D Gary Gilliland; Harvey Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

3.  Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen.

Authors:  Els Lierman; Helen Van Miegroet; Els Beullens; Jan Cools
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

Review 4.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

5.  Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.

Authors:  Andrew Chase; Catherine Bryant; Joannah Score; Nicholas C P Cross
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

6.  Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.

Authors:  Andrew Chase; Catherine Bryant; Joannah Score; Claudia Haferlach; Vera Grossmann; Juliana Schwaab; Wolf-Karsten Hofmann; Andreas Reiter; Nicholas C P Cross
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

7.  14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.

Authors:  Shaozhong Dong; Sumin Kang; Ting-Lei Gu; Sean Kardar; Haian Fu; Sagar Lonial; Hanna Jean Khoury; Fadlo Khuri; Jing Chen
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

8.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

9.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

10.  Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS.

Authors:  Chitta Kasyapa; Ting-Lei Gu; Lalitha Nagarajan; Lalitha Natarajan; Roberto Polakiewicz; John K Cowell
Journal:  Proteomics       Date:  2009-08       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.